BioCryst & Celgene Suffer English Funding Setback For Rare Disease Drugs
NICE’s Recommendations Are Out For Consultation until 28 July
Executive Summary
Orladeyo and Inrebic have been approved in Great Britain but they will not be available under the National Health Service unless their manufacturers can convince the health technology assessment body, NICE, that their products are cost-effective.
You may also be interested in...
BioCryst Says Orladeyo On Slow, Steady Ramp To Blockbuster Sales
Company believes its oral HAE prophylaxis will gradually reach the billion-dollar sales threshold, with about 80% of revenue coming from the US market.
New Sickle Cell Treatment & Ten Other Drugs Win English Funding Approval
Health technology assessment body NICE has also issued guidances rejecting three products.
UK Early Access For BioCryst’s Hereditary Angioedema Drug
The HAE product, which meets the four criteria for pre-licensing use under the UK’s early access scheme, is currently undergoing regulatory evaluation in the EU, the US and Japan, with approval decisions expected in the last two countries next month.